Health science solutions provider Revvity Inc (NYSE: RVTY) announced on Monday that it has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software supporting analytical characterisation and molecular design in pharmaceutical and material sciences. The acquisition, expected to close in late Q4 2025, expands Revvity Signals' capabilities across research informatics and development workflows, enhancing its ability to convert complex analytical data into actionable insights.

ACD/Labs' portfolio includes the Spectrus platform for advanced spectral analysis, the Percepta platform for AI-driven molecular property and ADMET prediction, and other tools for high-throughput experimentation, pharmaceutical chemistry, manufacturing decision support, and enterprise analytical data management. Integration with Revvity Signals aims to provide end-to-end support from discovery and development to scale-up and manufacturing, enabling scientists to interpret and act on data more efficiently.

Revvity, with 2024 revenue exceeding USD2.7bn and approximately 11,000 employees, delivers comprehensive health science solutions across pharmaceutical and biotech, diagnostic labs, academia and government customers in over 160 countries.

ACD/Labs brings 30 years of expertise in chemical and pharmaceutical R&D software, offering AI-ready, cloud-enabled, and FAIR-compliant tools designed to accelerate scientific innovation.